EGFR and glioma: Another PARP-1 inhibitor, talazoparib, increased DNA damage and PARP–DNA trapping, enhancing cytotoxicity against EGFR-amplified glioma sphere-forming cells, Additionally, it reduced tumor growth significantly in EGFR-amplified subcutaneous models but not in nonamplified models (Wu et al., 2020).